Citius Pharmaceuticals (CTXR) revenue and earnings history
Citius Pharmaceuticals's annual figures for 16 fiscal years, as filed with the SEC.
Revenue and net income, 16 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Sep 30, 2025 | — | −$38.5M | — | −$26.6M | — | — | $10.8M | — | — | $4.25M | — | 10-K |
| 2024ended Sep 30, 2024 | — |
The latest quarter, insider trades and fund moves: Citius Pharmaceuticals (CTXR) on OQRO.
Common questions
Has Citius Pharmaceuticals been profitable?
It reported a net loss in 11 of the years shown (2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023). The highest net income was −$738K in fiscal 2014.
Does Citius Pharmaceuticals buy back shares or pay dividends?
None of the 16 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Each year's figure here comes from the newest annual report that states it. After a stock split, earlier reports and later reports state per-share figures on different share counts, so a column of EPS would mix the two. Net income is not affected by splits.
Where these figures come from
The SEC’s companyfacts data: every figure Citius Pharmaceuticals tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.